478 related articles for article (PubMed ID: 25733162)
1. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.
Ishida T; Jo T; Takemoto S; Suzushima H; Uozumi K; Yamamoto K; Uike N; Saburi Y; Nosaka K; Utsunomiya A; Tobinai K; Fujiwara H; Ishitsuka K; Yoshida S; Taira N; Moriuchi Y; Imada K; Miyamoto T; Akinaga S; Tomonaga M; Ueda R
Br J Haematol; 2015 Jun; 169(5):672-82. PubMed ID: 25733162
[TBL] [Abstract][Full Text] [Related]
2. Mogamulizumab Plus EPOCH Therapy for Patients With Newly Diagnosed Aggressive Adult T-cell Leukemia/lymphoma.
Jo T; Matsuzaka K; Shioya H; Tominaga H; Sakai T; Kaneko Y; Hayashi S; Matsuo M; Taguchi J; Abe K; Shigematsu K; Kubota-Koketsu R
Anticancer Res; 2020 Sep; 40(9):5237-5243. PubMed ID: 32878812
[TBL] [Abstract][Full Text] [Related]
3. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
[TBL] [Abstract][Full Text] [Related]
4. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303.
Yamada Y; Tomonaga M; Fukuda H; Hanada S; Utsunomiya A; Tara M; Sano M; Ikeda S; Takatsuki K; Kozuru M; Araki K; Kawano F; Niimi M; Tobinai K; Hotta T; Shimoyama M
Br J Haematol; 2001 May; 113(2):375-82. PubMed ID: 11380402
[TBL] [Abstract][Full Text] [Related]
5. Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T-cell leukaemia-lymphoma.
Ohno N; Kobayashi S; Ishigaki T; Yuji K; Kobayashi M; Sato K; Watanabe N; Tojo A; Uchimaru K
Br J Haematol; 2013 Dec; 163(5):683-5. PubMed ID: 23998261
[No Abstract] [Full Text] [Related]
6. Adult T-cell leukemia-lymphoma.
Tsukasaki K
Hematology; 2012 Apr; 17 Suppl 1():S32-5. PubMed ID: 22507774
[TBL] [Abstract][Full Text] [Related]
7. A case of post-mogamulizumab relapse of acute-type adult T-cell leukemia/lymphoma successfully treated with mogamulizumab and etoposide.
Sekiguchi Y; Shimada A; Ichikawa K; Wakabayashi M; Sugimoto K; Kinoshita A; Suga Y; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2014; 7(9):6278-90. PubMed ID: 25337281
[TBL] [Abstract][Full Text] [Related]
8. Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014).
Kawano N; Kuriyama T; Sonoda KH; Yoshida S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
Intern Med; 2016; 55(11):1439-45. PubMed ID: 27250049
[TBL] [Abstract][Full Text] [Related]
9. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).
Ceesay MM; Matutes E; Taylor GP; Fields P; Cavenagh J; Simpson S; Ho A; Devereux S; Mufti GJ; Pagliuca A
Leuk Res; 2012 Jul; 36(7):857-61. PubMed ID: 22209076
[TBL] [Abstract][Full Text] [Related]
10. Adult T-Cell Leukemia/Lymphoma.
Mehta-Shah N; Ratner L; Horwitz SM
J Oncol Pract; 2017 Aug; 13(8):487-492. PubMed ID: 28796966
[TBL] [Abstract][Full Text] [Related]
11. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT; Lewis DJ; Duvic M
Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
[TBL] [Abstract][Full Text] [Related]
12. [Haploidentical transplantation using post-transplant high-dose cyclophosphamide for adult T-cell lymphoma after mogamulizumab treatment].
Kusakabe M; Kurita N; Nishikii H; Sato R; Yoshida C; Yokoyama Y; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
Rinsho Ketsueki; 2017; 58(5):449-454. PubMed ID: 28592758
[TBL] [Abstract][Full Text] [Related]
13. Mogamulizumab
Phillips AA; Fields PA; Hermine O; Ramos JC; Beltran BE; Pereira J; Wandroo F; Feldman T; Taylor GP; Sawas A; Humphrey J; Kurman M; Moriya J; Dwyer K; Leoni M; Conlon K; Cook L; Gonsky J; Horwitz SM;
Haematologica; 2019 May; 104(5):993-1003. PubMed ID: 30573506
[TBL] [Abstract][Full Text] [Related]
14. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
[TBL] [Abstract][Full Text] [Related]
15. Clinical Features and Treatment Outcomes of 81 Patients with Aggressive Type Adult T-cell Leukemia-lymphoma at a Single Institution over a 7-year Period (2006-2012).
Kawano N; Yoshida S; Kuriyama T; Tahara Y; Yamashita K; Nagahiro Y; Kawano J; Koketsu H; Toyofuku A; Manabe T; Beppu K; Ono N; Himeji D; Yokota-Ikeda N; Inoue S; Ochiai H; Sonoda KH; Shimoda K; Ishikawa F; Ueda A
Intern Med; 2015; 54(12):1489-98. PubMed ID: 26073237
[TBL] [Abstract][Full Text] [Related]
16. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
Ribrag V; Gisselbrecht C; Haioun C; Salles G; Golfier JB; Ertault M; Ferme C; Briere J; Brice P; Mounier N
Cancer; 2009 Oct; 115(19):4540-6. PubMed ID: 19593797
[TBL] [Abstract][Full Text] [Related]
18. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
[TBL] [Abstract][Full Text] [Related]
19. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
Tsukasaki K; Utsunomiya A; Fukuda H; Shibata T; Fukushima T; Takatsuka Y; Ikeda S; Masuda M; Nagoshi H; Ueda R; Tamura K; Sano M; Momita S; Yamaguchi K; Kawano F; Hanada S; Tobinai K; Shimoyama M; Hotta T; Tomonaga M;
J Clin Oncol; 2007 Dec; 25(34):5458-64. PubMed ID: 17968021
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
Sakamoto Y; Ishida T; Masaki A; Murase T; Takeshita M; Muto R; Iwasaki H; Ito A; Kusumoto S; Nakano N; Tokunaga M; Yonekura K; Tashiro Y; Iida S; Utsunomiya A; Ueda R; Inagaki H
Br J Haematol; 2021 Nov; 195(4):571-584. PubMed ID: 34405395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
